-
1
-
-
3042820411
-
Renal cell carcinoma
-
Curti B. Renal cell carcinoma. JAMA 2004; 292: 97-100.
-
(2004)
JAMA
, vol.292
, pp. 97-100
-
-
Curti, B.1
-
3
-
-
0033978220
-
Systemic therapy for renal cell carcinoma
-
Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 2000; 163: 408-417.
-
(2000)
J. Urol.
, vol.163
, pp. 408-417
-
-
Motzer, R.J.1
Russo, P.2
-
4
-
-
0027192081
-
Immunotherapy for metastatic renal cell carcinoma
-
Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am. 1993; 20: 283-295.
-
(1993)
Urol. Clin. North Am.
, vol.20
, pp. 283-295
-
-
Wirth, M.P.1
-
5
-
-
0029090362
-
Phase III randomized trial of interleukin-2 with or without linphokine-activated killer sense in the treatment of patients with advanced renal cell carcinoma
-
Law TM, Motzer RJ, Mazumdar M etal. Phase III randomized trial of interleukin-2 with or without linphokine-activated killer sense in the treatment of patients with advanced renal cell carcinoma. Cancer 1996; 76: 824-832.
-
(1996)
Cancer
, vol.76
, pp. 824-832
-
-
Law, T.M.1
Motzer, R.J.2
Mazumdar, M.3
-
6
-
-
0027199879
-
Subcutaneous interleukin-2 plus interferon-α- in metastatic renal cancer
-
Vogelzang NJ, Lipton A, Figlin RA etal. Subcutaneous interleukin-2 plus interferon-α- in metastatic renal cancer. J. Clin. Oncol. 1993; 11: 1809-1816.
-
(1993)
J. Clin. Oncol.
, vol.11
, pp. 1809-1816
-
-
Vogelzang, N.J.1
Lipton, A.2
Figlin, R.A.3
-
7
-
-
0033056820
-
Citokines in metastatic renal cell carcinoma
-
Escudier B, Chevreau C, Lasset C etal. Citokines in metastatic renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2039-2043.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 2039-2043
-
-
Escudier, B.1
Chevreau, C.2
Lasset, C.3
-
8
-
-
0035835819
-
The von Hippel-Lindau tumor suppressor gene
-
Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp. Cell Press 2001; 264: 117-125.
-
(2001)
Exp. Cell Press
, vol.264
, pp. 117-125
-
-
Kondo, K.1
Kaelin Jr., W.G.2
-
9
-
-
18344396226
-
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma
-
Kondo K, Yao M, Yoshida M etal. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma. Genes Chromosomes Cancer 2002; 34: 58-68.
-
(2002)
Genes Chromosomes Cancer
, vol.34
, pp. 58-68
-
-
Kondo, K.1
Yao, M.2
Yoshida, M.3
-
10
-
-
0037307858
-
The von Hippel-Lindau tumor suppression protein: new insights into oxygen sensing and cancer
-
Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor suppression protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 2003; 13: 55-60.
-
(2003)
Curr. Opin. Genet. Dev.
, vol.13
, pp. 55-60
-
-
Kim, W.1
Kaelin Jr., W.G.2
-
11
-
-
78650874372
-
Sunitinib inhibits KIN and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer
-
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. Sunitinib inhibits KIN and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003; 2: 471-478.
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
Pryer, N.K.4
Cherrington, J.M.5
-
12
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
O'Farrel AM, Abrams TJ, Yuen HA etal. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
-
(2003)
Blood
, vol.101
, pp. 3597-3605
-
-
O'Farrel, A.M.1
Abrams, T.J.2
Yuen, H.A.3
-
13
-
-
0345359585
-
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients
-
O'Farrel AM, Foran JM, Fiedler W etal. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 2003; 9: 5465-5476.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 5465-5476
-
-
O'Farrel, A.M.1
Foran, J.M.2
Fiedler, W.3
-
14
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors
-
Mendel DB, Laird AD, Xin X etal. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin. Cancer Res. 2003; 9: 327-337.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
-
15
-
-
37249072373
-
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1 week off period
-
Britten CD, Kabbinavar F, Hecht JR etal. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1 week off period. Cancer Chemoter Pharmacol. 2008; 61: 515-524.
-
(2008)
Cancer Chemoter Pharmacol.
, vol.61
, pp. 515-524
-
-
Britten, C.D.1
Kabbinavar, F.2
Hecht, J.R.3
-
16
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Ins. 2000; 92: 205-216.
-
(2000)
J. Natl. Cancer Ins.
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
17
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989; 10: 1-10.
-
(1989)
Control. Clin. Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
18
-
-
33845382806
-
Non-parametric estimation from incomplete observation
-
Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc. 1958; 53: 457-481.
-
(1958)
J. Am. Stat. Assoc.
, vol.53
, pp. 457-481
-
-
Kaplan, E.1
Meier, P.2
-
19
-
-
84877348319
-
Extract confidence limits
-
Geigy scientific tables
-
Lentner C. Extract confidence limits. Geigy scientific tables 1982;89-102.
-
(1982)
, pp. 89-102
-
-
Lentner, C.1
-
20
-
-
1442290393
-
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
-
Motzer RJ, Bacik J, Schwartz LH etal. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2004; 22: 454-463.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 454-463
-
-
Motzer, R.J.1
Bacik, J.2
Schwartz, L.H.3
-
21
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
Motzer RJ, Brian I, Ronald M etal. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
-
(2006)
JAMA
, vol.295
, pp. 2516-2524
-
-
Motzer, R.J.1
Brian, I.2
Ronald, M.3
-
22
-
-
2442669093
-
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
-
Abrams TJ, Murray LJ, Pesenti E etal. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2003; 2: 1011-1021.
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 1011-1021
-
-
Abrams, T.J.1
Murray, L.J.2
Pesenti, E.3
-
23
-
-
19944431093
-
A phase I study of SU 11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease
-
Fielder W, Seve H, Dohner H etal. A phase I study of SU 11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-993.
-
(2005)
Blood
, vol.105
, pp. 986-993
-
-
Fielder, W.1
Seve, H.2
Dohner, H.3
-
24
-
-
70249084594
-
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
-
Escudier B, Roigas J, Gillssen S etal. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 4068-4075.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4068-4075
-
-
Escudier, B.1
Roigas, J.2
Gillssen, S.3
-
25
-
-
84863116418
-
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
-
Barrios CH, Hernandez-Barajas D, Brown MP etal. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012; 118: 1252-1259.
-
(2012)
Cancer
, vol.118
, pp. 1252-1259
-
-
Barrios, C.H.1
Hernandez-Barajas, D.2
Brown, M.P.3
|